Reuters logo
BRIEF-Heron Therapeutics granted FDA fast track designation for HTX-011
October 26, 2017 / 1:06 PM / a month ago

BRIEF-Heron Therapeutics granted FDA fast track designation for HTX-011

Oct 26 (Reuters) - Heron Therapeutics Inc

* Heron Therapeutics granted FDA fast track designation for HTX-011 to reduce postoperative pain and the need for opioid analgesics for 72 hours

* Heron Therapeutics Inc - ‍Phase 3 studies for HTX-011 ongoing; NDA filing planned for 2018​

* Heron Therapeutics - ‍expect to report top-line results from pivotal phase 3 studies in first half of 2018 and file for FDA review in second half of 2018​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below